Form 8.3 - The Vanguard Group, Inc.: Allergan plc (1041089)

 
 The Vanguard Group, Inc. (IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Allergan plc 
 
11-May-2020 / 14:43 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
              Ap19 
 
              FORM 8.3 
 
IRISH TAKEOVER PANEL 
******************** 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER 
RULES, 2013 
****************************************************************************** 
******* 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% 
OR MORE 
****************************************************************************** 
****** 
 
1. KEY INFORMATION 
****************** 
 
Name of person dealing (Note 1)        The Vanguard Group, Inc. 
Company dealt in                       Allergan plc 
Class of relevant security to which    US$0.0001 Ordinary Shares 
the dealings being disclosed relate 
(Note 2) 
Date of dealing                        08 May 2020 
 
2. INTERESTS AND SHORT POSITIONS 
 
(a) Interests and short positions (following dealing) in the class of relevant 
security dealt in (Note 3) 
 
                                  Long               Short 
                           Numbers    (%)      Numbers  (%) 
(1) Relevant securities    25,034,928 7.61% 
(2) Derivatives (other 
than options) 
(3) Options and agreements 
to purchase/sell 
Total                      25,034,928 7.61% 
 
(b) Interests and short positions in relevant securities of the company, other 
than the class dealt in (Note 3) 
 
Class of relevant security:        Long              Short 
                             Numbers  (%)      Numbers  (%) 
(1) Relevant securities 
(2) Derivatives (other than 
options) 
(3) Options and agreements 
to purchase/sell 
Total 
 
Ap20 
 
1. Dealings (Note 4) 
 
(a) Purchases and sales 
 
Purchase/sale     Number of relevant       Price per unit (Note 
                      securities                    5) 
Sale          3,156                       192.99 USD 
Purchase      2,204                       192.99 USD 
 
(b) Derivatives transactions (other than options transactions) 
 
Product name,  Nature of        Number of         Price per 
               transaction      relevant          unit 
                                securities 
 
e.g. CFD 
               (Note 6)                           (Note 5) 
                                (Note 7) 
Not Applicable 
 
(c) Options transactions in respect of existing relevant securities 
 
(i) Writing, selling, purchasing or varying 
 
Product   Writing, Number   Exercise  Type,  Expiry     Option 
name,     selling, of       price     e.g.   date       money 
          purchasi securiti           Americ            paid/rec 
          ng,      es to              an,               eived 
          varying  which              Europe            per unit 
e.g. call etc.     the                an                (Note 5) 
option             option             etc. 
                   relates 
                   (Note 7) 
Not 
Applicabl 
e 
 
(ii) Exercising 
 
Product name,    Number of securities Exercise price per unit 
                                      (Note 5) 
 
e.g. call option 
 
Not Applicable 
 
(e) Other dealings (including transactions in respect of new securities) (Note 
4) 
 
Nature of transaction Details Price per unit 
 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 
 
              Ap21 
 
2. OTHER INFORMATION 
 
Agreements, arrangements or understandings relating to options or derivatives 
 
Full details of any agreement, arrangement or understanding 
between the person disclosing and any other person relating to 
the voting rights of any relevant securities under any option 
referred to on this form or relating to the voting rights or 
future acquisition or disposal of any relevant securities to 
which any derivative referred to on this form is referenced. If 
none, this should be stated. 
 
Is a Supplemental Form 8 attached? (Note 9) NO 
 
Date of disclosure                              11 May 2020 
Contact name                                    Shawn Acker 
Telephone number                                001-610-669-8989 
If a connected EFM, name of offeree/offeror 
with which connected 
If a connected EFM, state nature of connection 
(Note 10) 
 
Category Code: RET - Allergan plc 
TIDM:          IRSH 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  62856 
EQS News ID:   1041089 
 
End of Announcement EQS News Service
(END) Dow Jones Newswires
May 11, 2020 09:43 ET (13:43 GMT)
Allergan (LSE:0Y7T)
過去株価チャート
から 12 2024 まで 1 2025